UltraSight has closed a $13 million funding round that will be used to advance U.S. clinical programs for the company's real-time artificial intelligence (AI) guidance technology in a variety of care settings.
The company's AI platform provides the engine for ultrasound devices to conduct sonography at the point of care, helping patients be accurately diagnosed and treated, according to the company. The Yozma Group Korea, Atain Specialty Insurance Company, and the Weizmann Institute of Science participated in the round.
The company also announced new appointments to its medical and scientific advisory board. These include Al Lojewski, former general manager of cardiology solutions at GE Healthcare; Dr. Laurance Grossman, radiologist at Cleveland Clinic; and Andrew Cleeland, CEO of Fogarty Innovation.
